Tafenoquine May Improve Clinical Recovery Time for Patients With COVID-19
Researchers assessed the efficacy of tafenoquine for the treatment of mild to moderate COVID-19 infection.
Researchers assessed the efficacy of tafenoquine for the treatment of mild to moderate COVID-19 infection.
How does COVID-19 vaccination affect individuals with post-acute sequelae of COVID-19 with respect to symptom control and immune response?
A U.S. FDA recommended on Tuesday that updated COVID-19 booster shots be used this fall to protect against omicron and its highly contagious subvariants.
Researchers assessed antibody responses among health care workers 9 months after COVID-19 vaccination.
For children aged 5 to 11 years, two doses of BNT162b2 provide moderate protection against documented SARS-CoV-2 infection and symptomatic COVID-19.
The researchers identified 265,339 hospital contacts: 44, 21, and 35 percent for coronary artery disease, coagulation disorders, and cerebrovascular disease, respectively.
During the first year of COVID-19 vaccination, vaccines prevented 19.8 million deaths, using excess death as an estimate of the true extent of the pandemic.
The U.S. FDA’s vaccine advisory panel voted to recommend the agency approve the emergency use of Moderna’s COVID-19 vaccine in children aged 6 to 17.
Vaccine effectiveness against SARS-CoV-2 infection and symptomatic COVID-19 wanes over time, but remains strong against severe COVID-19.
Presenting at CMSC 2022, researchers evaluated COVID-19 outcomes among patients with MS who received treatment with ofatumumab.